Clinical Trials
25 trialsNCT05419011 2026-05-27
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07551596 2026-05-15
Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT05223036 2026-05-14
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02298959 2026-05-13
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04704661 2026-05-13
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05630794 2026-05-13
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05691491 2026-05-13
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05803382 2026-05-13
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06102902 2026-05-13
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06557733 2026-05-13
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06654037 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06696768 2026-05-13
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT07147231 2026-05-13
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07405476 2026-04-17
Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment
Emory University
Phase 2 Recruiting
NCT06269978 2026-03-10
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT05078866 2026-03-03
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04767984 2026-01-21
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Northwestern University
Phase 2 Active not recruiting
NCT07327489 2026-01-08
ELEPHAS-05
Elephas
Recruiting
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT04729322 2025-12-23
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00625066 2025-12-17
Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy
Vanderbilt University Medical Center
Completed
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07271355 2025-12-09
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
City of Hope Medical Center
Phase 3 Not yet recruiting
NCT06730100 2025-10-06
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn